Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.
Highlight Therapeutics announces completion of enrollment for Phase 2b study of BO-112 in large, underserved basal cell ...
In parallel, the Company is also engaged in significant pre-clinical work in partnership with leading academic institutions, including Mayo Clinic, McGill University, Emory University and MD Anderson ...
DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic ...
The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel Therapeutic ...
Gene therapy represents an innovative approach to treating cancer by directly modifying the genetic material within tumour cells, thereby utilising molecular mechanisms to inhibit tumour growth or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results